News & Media
Main Menu
Presentations
- All PRESENTATIONS
- AZP-3813
- Eneboparatide (AZP-3601)
All PRESENTATIONS
- All PRESENTATIONS
- AZP-3813
- Eneboparatide (AZP-3601)
Eneboparatide (AZP-3601)
Eneboparatide, a Novel PTH-1 Receptor Agonist, Has No Impact on Bone Parameters Following Chronic Treatment of Non-Human Primates. ECE 2023 Presentation.
Written by
Dan Hennings
Eneboparatide (AZP-3601)
Eneboparatide, a Novel PTH-1 Receptor Agonist, Induces Rapid Reduction and Normalization of Urinary Calcium in Chronic Hypoparathyroid Patients. ECE 2023 Poster.
Written by
Dan Hennings
Eneboparatide (AZP-3601)
Eneboparatide, a Novel PTH-1 Receptor Agonist, Induces Rapid Reduction and Normalization of Urinary Calcium in Chronic Hypoparathyroid Patients. ECE 2023 Presentation.
Written by
Dan Hennings
Eneboparatide (AZP-3601)
Treatment of Chronic Hypoparathyroidism by Eneboparatide, a Novel PTH Receptor-1 Agonist: Results from a Phase 2a Study. ECE 2023 Presentation.
Written by
Dan Hennings
Upcoming events
J.P. Morgan 42nd Annual Healthcare Conference (JPM)
Date: January 8-11, 2024 (San Francisco, CA)
Rare Disease Day
Date: February 29, 2024
26th European Congress of Endocrinology (ECE)
Date: May 11-14, 2024 (Stockholm, Sweden)
World Hypoparathyroidism Awareness Day
Date: June 1, 2024
2024 Endocrine Society Meeting (ENDO)
Date: June 1-4, 2024 (Boston, MA)
BIO International Convention
Date: June 3-6, 2024 (San Diego, CA)
American Society for Bone and Mineral Research 2024 Annual Meeting (ASBMR)
Date: September 27-30, 2024 (Toronto, Canada)
40th Congress of the French Society of Endocrinology
Date: October 16-18, 2024 (Clermont-Ferrand, France)
Acromegaly Awareness Day
Date: November 1, 2024
Social Updates
TWITTER